NovaSignal Corp., a Los Angeles, California-based medical technology and data company specializing in the assessment and management of brain health, closed $37 million in a Series C1 round of funding.
The funding round was led by Alpha Edison and Reimagined Ventures.
The company will use the capital to support NovaSignal’s continued commercial expansion, consistent delivery of product innovation, and new clinical trials to increase indications within and beyond stroke. The funding round was led by Alpha Edison and Reimagined Ventures.
Company: NovaSignal Corp.
Round: Series C1
Funding Month: September 2021
Lead Investors: Alpha Edison and Reimagined Ventures
Company Website: https://www.novasignal.com/
Software Category: Intelligent Ultrasound
About the Company: Founded in 2013, NovaSignal Corp. is a medical technology company whose mission is to save lives by unlocking the power of cerebral blood flow data. The company’s FDA-cleared NovaGuide Intelligent Ultrasound combines non-invasive ultrasound, robotics, and artificial intelligence to assess cerebral hemodynamics in real-time. Using cloud computing and data analytics, NovaSignal supports physicians in their clinical decision-making in several neurological conditions including stroke, traumatic brain injury, and dementia.